Orthopaedic Research UK (ORUK) has announced a £100,000 investment in VerIQ Limited, a UK-based MedTech clinical research accelerator, through a convertible loan agreement. The investment will help advance VerIQ’s mission to transform how medical device and health technology research is delivered; ensuring that exciting new innovations reach our patients faster, with uncompromising scientific integrity.
This strategic partnership reinforces ORUK’s commitment to improve musculoskeletal health and patient outcomes. The funding will enable VerIQ to expand its nationwide network of orthopaedic and MedTech clinical research sites, focusing initially on improved treatment for improved musculoskeletal health. This will strengthen the UK’s capability to deliver faster, higher-quality, and more cost-efficient clinical evidence and help get new products launched much sooner than is currently achieved.
The UK Government’s recently published Life Science Sector Plan highlighted the urgent need accelerate the delivery and reduce costs of conducting clinical studies in the UK. VerIQ has been designed to meet that need and will make a major difference to the ability of the UK to deliver world-leading clinical research for MedTech companies.
VerIQ Limited operates a coordinated, pre-qualified network of research-active hospitals and clinics supported by experienced investigators, research nurses, and academic partners. This “trial-ready” platform enables rapid study set-up, accelerated recruitment, and consistent, high-quality data delivery, addressing long-standing bottlenecks in MedTech evaluation. By utilising the world-leading academic and clinical resources in the UK, but in a package specifically designed for MedTech innovation, VerIQ aims to become a world leader in the rapid, efficient delivery of MedTech clinical research.
Dr Arash Angadji, Chief Executive Officer of Orthopaedic Research UK, said:
“Orthopaedic Research UK is dedicated to advancing research and innovation that directly benefits patients living with musculoskeletal conditions. Our investment in VerIQ represents a strategic step toward a more connected and efficient research ecosystem — one that accelerates the generation of high-quality clinical evidence and supports the safe, timely introduction of new technologies into clinical practice”
Dr Joe Dupere, Chief Executive Officer of VerIQ Limited, added:
“We’re delighted to welcome Orthopaedic Research UK as a strategic investor and partner. ORUK’s commitment to evidence-based innovation perfectly aligns with our vision to redefine how MedTech trials are designed and delivered. This investment enables us to expand our infrastructure and help innovators — from early-stage developers to global companies — bring breakthrough technologies to patients faster and more efficiently.”
Professor Andy Metcalfe, Medical Director and Founder of VerIQ said:
“Orthopaedic Research UK is a leading voice in musculoskeletal innovation in the UK and I am delighted to be working with them to deliver this exciting vision. Bone and joint problems are one of the world’s main causes of pain and disability and orthopaedic devices such as hip and knee replacements can transform people’s lives. It’s critical that we support the MedTech industry to deliver the new treatments and devices that people need and VerIQ will ensure the UK leads the world in delivering high-quality patient-focused research that brings the best innovation to patients quickly and safely.”
The convertible loan will support VerIQ’s next phase of growth, including the expansion of its clinical site network, deployment of advanced digital trial management infrastructure, and development of new partnerships across the orthopaedic and wider MedTech landscape.
About Orthopaedic Research UK (ORUK)
Orthopaedic Research UK is a medical research charity dedicated to advancing the understanding, prevention, and treatment of bone, joint, and muscle disorders. ORUK funds research, education, and innovation to reduce the burden of musculoskeletal conditions and improve patient lives. ORUK is first MSK charity in the UK to actively support early-stage start-ups. It invests in entrepreneurs delivering breakthrough innovations within MSK health and helps accelerate the translation of research ideas into new products or services by providing Early Career Researchers with education, mentoring, investment and networking support.
Learn more: www.oruk.org
About VerIQ Limited
VerIQ Limited is a UK-based MedTech clinical trial accelerator built to unlock faster, higher-quality clinical research. Through a coordinated network of pre-qualified trial sites, research nurses, and clinical investigators, VerIQ enables rapid study set-up, accelerated recruitment, and consistent data quality. Backed by a leadership team with deep expertise in complex and innovative trials, VerIQ partners with MedTech developers — from early innovators to global multinationals — to design and deliver clinical studies on time and on budget.
Learn more: www.veriq.co.uk